LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Aandelen Lijst・Incyte Corp
Search

Incyte Corp

Open

SectorGezondheidszorg

100.62 -1.69

Buy

Prijsupdate 9 jun 2026, 13:31 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

98.54

Max

104.46

Belangrijke statistieken

By Trading Economics

Inkomsten

4.1M

303M

Verkoop

-234M

1.3B

K/W

Sectorgemiddelde

13.501

49.888

EPS

1.81

Winstmarge

23.834

Werknemers

2,844

EBITDA

-47M

368M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+9.36% upside

Dividenden

By Dow Jones

Volgende Winsten

28 jul 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

49M

19B

Vorige openingsprijs

102.31

Vorige sluitingsprijs

100.62

Nieuwssentiment

By Acuity

47%

53%

151 / 344 Rangschikking in Healthcare

Incyte Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 jun 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

DJ

Lezen

8 jun 2026, 15:41 UTC

Belangrijke Marktbewegers

American Battery Shares Jump on Energy Department Victory

DJ

Lezen

8 jun 2026, 23:46 UTC

Marktinformatie

Nikkei May Rebound After Monday's Selloff -- Market Talk

DJ

Lezen

8 jun 2026, 23:37 UTC

Marktinformatie

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

DJ

Lezen

8 jun 2026, 23:25 UTC

Marktinformatie

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

DJ

Lezen

8 jun 2026, 23:25 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

8 jun 2026, 21:57 UTC

Acquisities, Fusies, Overnames

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

DJ

Lezen

8 jun 2026, 21:56 UTC

Acquisities, Fusies, Overnames

Salesforce Agrees to Buy m3ter

DJ

Lezen

8 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

DJ

Lezen

8 jun 2026, 19:22 UTC

Marktinformatie

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

DJ

Lezen

8 jun 2026, 19:01 UTC

Marktinformatie

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

DJ

Lezen

8 jun 2026, 18:52 UTC

Marktinformatie

Global Energy Roundup: Market Talk

DJ

Lezen

8 jun 2026, 18:52 UTC

Marktinformatie

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

DJ

Lezen

8 jun 2026, 18:17 UTC

Marktinformatie

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

DJ

Lezen

8 jun 2026, 17:32 UTC

Marktinformatie

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

DJ

Lezen

8 jun 2026, 17:29 UTC

Marktinformatie

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

DJ

Lezen

8 jun 2026, 17:29 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

8 jun 2026, 16:55 UTC

Acquisities, Fusies, Overnames

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

DJ

Lezen

8 jun 2026, 16:54 UTC

Acquisities, Fusies, Overnames

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

DJ

Lezen

8 jun 2026, 16:40 UTC

Marktinformatie

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

DJ

Lezen

8 jun 2026, 16:31 UTC

Marktinformatie

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

DJ

Lezen

8 jun 2026, 16:27 UTC

Marktinformatie

Mexican Inflation Seen Easing in May -- Market Talk

DJ

Lezen

8 jun 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

DJ

Lezen

8 jun 2026, 16:03 UTC

Acquisities, Fusies, Overnames

Orange Bought Stake From Lorca

DJ

Lezen

8 jun 2026, 16:01 UTC

Acquisities, Fusies, Overnames

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

DJ

Lezen

8 jun 2026, 16:01 UTC

Acquisities, Fusies, Overnames

Orange Acquires 100% Ownership of MasOrange

DJ

Lezen

8 jun 2026, 15:58 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

8 jun 2026, 15:58 UTC

Marktinformatie

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

DJ

Lezen

8 jun 2026, 15:55 UTC

Marktinformatie

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

DJ

Lezen

8 jun 2026, 15:41 UTC

Marktinformatie

Gold Falls Below 200-Day Moving Average -- Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Incyte Corp Prognose

Koersdoel

By TipRanks

9.36% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 110.06 USD  9.36%

Hoogste 135 USD

Laagste 75 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Incyte Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

19 ratings

8

Buy

10

Hold

1

Sell

Gebaseerd op 19 analisten die aandelenratings hebben gegeven aan Incyte Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

151 / 344 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,144.58

↑ +1.28%

JNJ

Johnson and Johnson

232.3

↓-0.15%

ABBV

AbbVie Inc

222.66

↓-2.06%

UNH

UnitedHealth Group Inc

405.72

↑ +1.35%

MRK

Merck & Co Inc.

119.23

↓-1.41%
help-icon Live chat